Keywords: Achillion, Hepatitis C, ACH-3102, USA, FDA, Fast-track
US FDA fast-tracks Achillion's hepatitis C drug candidate
Article | 15 May 2012
USA-based Achillion Pharmaceuticals (Nasdaq: ACHN) says it has received Fast Track designation from the Food and Drug Administration for ACH-3102 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
